## EilÃ-s Dowd

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3673353/publications.pdf Version: 2024-02-01



FILÃS DOMD

#	Article	IF	CITATIONS
1	Time-Course of Alterations in the Endocannabinoid System after Viral-Mediated Overexpression of α-Synuclein in the Rat Brain. Molecules, 2022, 27, 507.	3.8	6
2	The potential of biomaterials for central nervous system cellular repair. Neurochemistry International, 2021, 144, 104971.	3.8	20
3	Back to the future: lessons from past viral infections and the link with Parkinson's disease. Neuronal Signaling, 2021, 5, NS20200051.	3.2	3
4	Anti-inflammatory cytokine-eluting collagen hydrogel reduces the host immune response to dopaminergic cell transplants in a rat model of Parkinson's disease. Neuronal Signaling, 2021, 5, NS20210028.	3.2	4
5	Growth Factor Therapy for Parkinson's Disease: Alternative Delivery Systems. Journal of Parkinson's Disease, 2021, 11, S229-S236.	2.8	4
6	The Small Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein Pathology in Subclinical AAV Rat Models. Biomolecules, 2021, 11, 1685.	4.0	3
7	Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson's Disease. Molecules, 2020, 25, 453.	3.8	30
8	Encapsulation of young donor age dopaminergic grafts in a <scp>GDNF</scp> â€loaded collagen hydrogel further increases their survival, reinnervation, and functional efficacy after intrastriatal transplantation in hemiâ€Parkinsonian rats. European Journal of Neuroscience, 2019, 49, 487-496.	2.6	30
9	In memory of Tom Isaacs: The epitomical mover and shaker. European Journal of Neuroscience, 2019, 49, 303-303.	2.6	1
10	Gamma Band Light Stimulation in Human Case Studies: Groundwork for Potential Alzheimer's Disease Treatment. Journal of Alzheimer's Disease, 2019, 70, 171-185.	2.6	43
11	Viral mimetic priming enhances α-synuclein-induced degeneration: Implications for Parkinson's disease. Brain, Behavior, and Immunity, 2019, 80, 525-535.	4.1	16
12	Harnessing stem cells and biomaterials to promote neural repair. British Journal of Pharmacology, 2019, 176, 355-368.	5.4	34
13	Harnessing stem cells and biomaterials to promote neural repair. British Journal of Pharmacology, 2019, 176, 355-368.	5.4	1
14	Primary tissue for cellular brain repair in Parkinson's disease: Promise, problems and the potential of biomaterials. European Journal of Neuroscience, 2019, 49, 472-486.	2.6	18
15	Preparation of Cytocompatible ITO Neuroelectrodes with Enhanced Electrochemical Characteristics Using a Facile Anodic Oxidation Process. Advanced Functional Materials, 2018, 28, 1605035.	14.9	16
16	A role for viral infections in Parkinson's etiology?. Neuronal Signaling, 2018, 2, NS20170166.	3.2	37
17	Brain repair for Parkinson's disease: is the answer in the matrix?. Neural Regeneration Research, 2018, 13, 1187	3.0	10
18	Time-course of striatal Toll-like receptor expression in neurotoxic, environmental and inflammatory rat models of Parkinson's disease. Journal of Neuroimmunology, 2017, 310, 103-106.	2.3	20

EilÃs Dowd

#	Article	IF	CITATIONS
19	Interaction between subclinical doses of the Parkinson's disease associated gene, α -synuclein , and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats. Behavioural Brain Research, 2017, 316, 160-168.	2.2	19
20	Encapsulation of primary dopaminergic neurons in a GDNF-loaded collagen hydrogel increases their survival, re-innervation and function after intra-striatal transplantation. Scientific Reports, 2017, 7, 16033.	3.3	67
21	Polyhydroxyalkanoate/carbon nanotube nanocomposites: flexible electrically conducting elastomers for neural applications. Nanomedicine, 2016, 11, 2547-2563.	3.3	37
22	Targeting delivery in Parkinson's disease. Drug Discovery Today, 2016, 21, 1313-1320.	6.4	15
23	Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease. Experimental Neurology, 2016, 283, 204-212.	4.1	46
24	Differential pattern of motor impairments in neurotoxic, environmental and inflammation-driven rat models of Parkinson's disease. Behavioural Brain Research, 2016, 296, 451-458.	2.2	7
25	Central CB <sub>2</sub> receptors in inflammation-driven neurodegeneration: dysregulation and therapeutic potential. Neural Regeneration Research, 2016, 11, 1409.	3.0	3
26	Fibrin As a Scaffold for Delivery of GDNF Overexpressing Stem Cells to the Adult Rat Brain. ACS Biomaterials Science and Engineering, 2015, 1, 559-566.	5.2	9
27	Fibrin-based microsphere reservoirs for delivery of neurotrophic factors to the brain. Nanomedicine, 2015, 10, 765-783.	3.3	32
28	Cannabinoids in Parkinson's disease. , 2015, , 35-59.		7
29	GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson's disease. Neuroscience, 2015, 303, 402-411.	2.3	74
30	Differential upregulation of the cannabinoid CB2 receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease. Experimental Neurology, 2015, 269, 133-141.	4.1	87
31	Heat Shock Protein 70 Reduces αâ€Synucleinâ€Induced Predegenerative Neuronal Dystrophy in the αâ€Synuclein Viral Gene Transfer Rat Model of Parkinson's Disease. CNS Neuroscience and Therapeutics, 2014, 20, 50-58.	3.9	33
32	Untying a nanoscale knotted polymer structure to linear chains for efficient gene delivery in vitro and to the brain. Nanoscale, 2014, 6, 7526-7533.	5.6	28
33	Biomaterial approaches to gene therapies for neurodegenerative disorders of the CNS. Biomaterials Science, 2013, 1, 556.	5.4	19
34	The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats. Behavioural Brain Research, 2013, 243, 6-15.	2.2	26
35	The reduction in immunogenicity of neurotrophin overexpressing stem cells after intra-striatal transplantation by encapsulation inÂanÂinÂsitu gelling collagen hydrogel. Biomaterials, 2013, 34, 9420-9429.	11.4	75
36	GDNF Gene Delivery via a 2-(Dimethylamino)ethyl Methacrylate Based Cyclized Knot Polymer for Neuronal Cell Applications. ACS Chemical Neuroscience, 2013, 4, 540-546.	3.5	32

EilÃs Dowd

#	Article	IF	CITATIONS
37	Further characterisation of the LPS model of Parkinson's disease: A comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat. Brain, Behavior, and Immunity, 2013, 27, 91-100.	4.1	100
38	The neurotoxicity of gene vectors and its amelioration by packaging with collagen hollow spheres. Biomaterials, 2013, 34, 2130-2141.	11.4	37
39	Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone. Neuroscience, 2012, 203, 170-179.	2.3	36
40	Nigral grafts in animal models of Parkinson's disease. Is recovery beyond motor function possible?. Progress in Brain Research, 2012, 200, 113-142.	1.4	9
41	Kinetics of thermally induced heat shock protein 27 and 70 expression by bone marrowâ€derived mesenchymal stem cells. Protein Science, 2012, 21, 904-909.	7.6	34
42	Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat. Neuroscience, 2011, 175, 251-261.	2.3	121
43	Characterisation of a novel model of Parkinson's disease by intra-striatal infusion of the pesticide rotenone. Neuroscience, 2011, 181, 234-242.	2.3	32
44	Human Amniocytes Regulate Serotonin Levels by Active Uptake and Express Genes Suggestive of a Wider Role in Facilitating Neurotransmitter Regulation in the Fetal Environment. Stem Cells and Development, 2011, 20, 341-349.	2.1	3
45	Potential of rat bone marrow-derived mesenchymal stem cells as vehicles for delivery of neurotrophins to the Parkinsonian rat brain. Brain Research, 2010, 1359, 33-43.	2.2	75
46	The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats. Brain Research, 2010, 1363, 40-48.	2.2	36
47	Inhibition by Anandamide of 6-Hydroxydopamine-Induced Cell Death in PC12 Cells. International Journal of Cell Biology, 2010, 2010, 1-10.	2.5	25
48	Survival and Immunogenicity of Mesenchymal Stem Cells From the Green Fluorescent Protein Transgenic Rat in the Adult Rat Brain. Neurorehabilitation and Neural Repair, 2010, 24, 645-656.	2.9	42
49	Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. Brain Research Bulletin, 2010, 81, 543-548.	3.0	42
50	Recovery of functional deficits following early donor age ventral mesencephalic grafts in a rat model of Parkinson's disease. Neuroscience, 2008, 154, 631-640.	2.3	46
51	Unilateral axonal or terminal injection of 6-hydroxydopamine causes rapid-onset nigrostriatal degeneration and contralateral motor impairments in the rat. Brain Research Bulletin, 2008, 77, 312-319.	3.0	33
52	Movement without dopamine: striatal dopamine is required to maintain but not to perform learned actions. Biochemical Society Transactions, 2007, 35, 428-432.	3.4	22
53	Further validation of the corridor task for assessing deficit and recovery in the hemi-Parkinsonian rat: Restoration of bilateral food retrieval by dopamine receptor agonism. Behavioural Brain Research, 2006, 169, 352-355.	2.2	23
54	Lentivectorâ€mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model. European Journal of Neuroscience, 2005, 22, 2587-2595.	2.6	84

EilÃs Dowd

#	Article	IF	CITATIONS
55	Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions in a lateralised nose-poking task in rats. Behavioural Brain Research, 2005, 159, 153-161.	2.2	45
56	Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions in rats using a lateralised nose-poking task with low stimulus–response compatibility. Behavioural Brain Research, 2005, 165, 181-186.	2.2	19
57	The Corridor Task: A simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum. Brain Research Bulletin, 2005, 68, 24-30.	3.0	86
58	Deficits in a lateralized associative learning task in dopamine-depleted rats with functional recovery by dopamine-rich transplants. European Journal of Neuroscience, 2004, 20, 1953-1959.	2.6	42
59	Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the β-amyloid peptide intracellularly in hippocampal and cortical neurons. Neuroscience, 2004, 129, 583-592.	2.3	91
60	Activation of P2X receptors for adenosine triphosphate evokes cardiorespiratory reflexes in anaesthetized rats. Journal of Physiology, 1998, 507, 843-855.	2.9	74
61	P2X receptor-mediated excitation of nociceptive afferents in the normal and arthritic rat knee joint. British Journal of Pharmacology, 1998, 125, 341-346.	5.4	132
62	Adenosine A1 receptor-mediated excitation of nociceptive afferents innervating the normal and arthritic rat knee joint. British Journal of Pharmacology, 1998, 125, 1267-1271.	5.4	28